Stanford University School of Medicine
Stanford, California, 94305, United States
NCT Number: NCT01970670
The primary objective is to determine how accurately one can estimate the size of the index tumor on preoperative imaging in patients with known breast cancer, using pathology as a reference standard. The primary endpoint, which will be measured on CEDM,and CE-MRI, is the maximum diameter (mm) of the index tumor.
Looking for future studies?
Notify Me18 year–70 year
Female
Observational
Stanford, California, 94305, United States
The primary objective is to determine how accurately one can estimate the size of the index tumor on preoperative imaging in patients with known breast cancer, using pathology as a reference standard. The primary endpoint, which will be measured on CEDM,and CE-MRI, is the maximum diameter (mm) of the index tumor.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Identify inclusion criteria
Identify exclusion criteria
i. Age > 70 ii. Diabetes iii. Personal history of renal disease iv. Family history of renal disease (e.g., polycystic kidney disease) v. Known solitary kidney vi. Other medical conditions that may affect the kidney (e.g., Lupus, multiple myeloma) c. Subject has taken metformin (Glucophage) within 48 hours of procedure d. Subject has had a prior reaction to iodinated contrast e. Subject has multiple allergies and/ or severe asthma regularly treated with medication f. Subject has had an episode of serious allergic reaction (anaphylaxis) to any substance
Time frame: up to 24 weeks
Stanford University
Other
Contrast-Enhanced Digital Mammography (CEDM) vs Contrast-Enhanced Breast MRI (CE-MRI) in Patients With Known Breast Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03162887
Breast - Female
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT03018080
Breast - Female, Breast Diseases
Charlotte, North Carolina, United States
View Trial DetailsNCT02601027
Breast - Female
Stanford, California, United States
View Trial DetailsNCT07273565
Breast - Female
Calgary, Canada
View Trial Details